Short Communication

Systemic inflammatory syndrome in children during COVID-19 pandemic in Ceará state, northeastern Brazil: an observational study

Luís Arthur Brasil Gadelha Farias[1], Magda Moura de Almeida[2],[3], Pâmela Maria Costa Linhares[2], Bruno Cavalcante Fales de Brito Alves[4], Roberto Jorge Colares Duarte Filho[3], Roberio Dias Leite[1],[3], Marco Aurelio Palazzi Safadi[5] and Luciano Pamplona de Góes Cavalcanti[3],[4]

[1]. Hospital São José de Doenças Infecciosas, Fortaleza, CE, Brasil.
[2]. Secretaria de Saúde do Estado do Ceará, Fortaleza, CE, Brasil.
[3]. Universidade Federal do Ceará, Faculdade de Medicina, Departamento de Saúde Comunitária, Fortaleza, CE, Brasil.
[4]. Centro Universitário Christus, Faculdade de Medicina, Fortaleza, CE, Brasil.
[5]. Santa Casa de São Paulo, Faculdade de Ciências Médicas, Departamento de Pediatria, São Paulo, SP, Brasil.

Abstract

In this study, we report the occurrence of multisystemic inflammatory syndrome among 64 children (2 deaths) with recent severe acute respiratory syndrome–related coronavirus 2 (SARS-COV-2) infections in the northeast region of Brazil. The major clinical symptoms and signs reported were exanthema (60.9%), abdominal pain (56.3%), nausea and vomiting (46.9%), diarrhea (37.5%), and dyspnea (37.5%). Laboratory findings revealed that the levels of C-reactive protein (75.0%), hemoglobin (51.6%), D-dimer (48.4%), lymphocytes (43.8%), LDH (45.3%), AST (42.2%), ALT (51.6%), and ferritin (48.4%) were above the reference values for a given age and gender. The clinical findings were similar to those observed in Kawasaki disease, although it represents a separate entity, emphasizing the need for proactive surveillance and early treatment.

Keywords: COVID-19. SARS-CoV-2. Multisystem inflammatory syndrome in children. Children.

Since the emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in China, in December 2019, the coronavirus disease 2019 (COVID-19) has affected more than 106 million people around the world1. Brazil was the most affected country in Latin America, with approximately 9.5 million cases and 230,000 SARS-CoV-2-associated deaths as of February 2021.2 COVID-19 was declared a pandemic by the World Health Organization on March 11 2020, representing the most challenging public health crisis faced by this generation2.

A striking feature of the COVID-19 pandemic is that relatively lower number of cases have been reported in children and adolescents as compared to adults3. Although most children and adolescents infected with SARS-CoV-2 are asymptomatic or present mild symptoms, in rare cases, children can be affected, and clinical manifestations may differ from those of adults. A rare, potentially severe case of multisystem inflammatory syndrome in children (MIS-C) was initially reported in the UK and then globally to occur days to weeks following the acute SARS-CoV-2 infection. MIS-C represents a growing concern in the pediatric population4.

The clinical characteristics of MIS-C share similar features with that of Kawasaki disease (KD), KD shock syndrome, macrophage activation syndrome (MAS), and toxic shock syndrome (TSS)4,5.

The state of Ceará in the northeast region was one of the most affected places in Brazil, with incidence rates of COVID-19 to be as high as 13,303/100,000 hab as of December 20206.

To further understand the epidemiological and clinical patterns of this rare syndrome in low- and middle-income countries, we provide in-detail description of all cases of MIS-C temporally associated with COVID-19 reported between May 1 and December 31, 2020, in the State of Ceará. Figure 1 shows the number and
temporal distribution of confirmed COVID-19 cases and deaths as of the epidemiological week of symptom onset in the state of Ceará, Brazil, 2020-2021.

We followed the case definition of MIS-C proposed by the Ministry of Health of Brazil, PAHO, and WHO, following the RECORD guidelines.

Hospitalized or fatal cases with: (1) Fever and elevated inflammatory markers within 3 days or more; (2) at least two of the following symptoms: i) rash or bilateral non-purulent conjunctivitis or mucocutaneous inflammation signs (oral, hands, or feet); ii) hypotension or shock; iii) features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including echocardiogram findings or elevated troponin or N-terminal pro B-type natriuretic peptide); iv) evidence of coagulopathy (elevated prothrombin time, partial thromboplastin time, and elevated D-dimers); and v) acute gastrointestinal problems (diarrhea, vomiting, or abdominal pain); (3) Elevated inflammatory markers such as C-reactive protein (PCR), Erythrocyte Sedimentation Rate (ESR), Lactate Dehydrogenase (LDH), ferritin, and procalcitonin; (4) Excluded cases with other microbial cause of inflammation; and (5) Positive RT-PCR, antigen test, or serology; or any contact with patients with COVID-19.

A total of 64 cases were included in the study, with 2 reported deaths (case-fatality rate of 3.1%). Most cases occurred in the month of July 2020 (n =31; 48.4%). About 48% of the patients were male. The median age was 7 years (range, 0–16 years). The cases occurred in 17 different municipalities, predominantly in Fortaleza, the capital of Ceará (42; 65.6%). These cases were reported by five hospitals, particularly from the reference hospital in the State, Albert Sabin Hospital (N = 41; 64.1%). The majority of cases had positive testing, either real-time reverse transcription polymerase chain reaction (RT-PCR) and/or antigen testing, from nasopharyngeal specimens and less frequently serologic testing for SARS-CoV-2 (Table 1).

Five cases reported comorbidities (7.8%), such as cardiovascular disease (n =2; 3.1%), hematological disease (n =1; 1.6%), neurological disease (n =1; 1.6%), and genetic syndrome (N=1, 1.6%). Data characterizing cardiopathy were absent; however, it was described as a rheumatic fever sequelae. Electrocardiogram was available in 11 (17.2%) patients, among which, one (1.6%) patient presented with ventricular hypertrophy. Echocardiography was performed in six patients (9.3%; n =6), wherein, two (3.1%) presented abnormalities, such as mild dilation of the left ventricle (N=1; 1.6%) and dilation of the left coronary trunk (N=1; 1.6%). Cardiac complications were reported in five (7.8%) patients: coronary aneurysm in two (3.1%), dilated cardiomyopathy in two (3.1%), and hypertrophic cardiomyopathy in one (1.6%). One of the patients with a history of cardiopathy presented with dilated cardiomyopathy.

The major clinical symptoms and signs reported were exanthema (N=39; 60.9%), abdominal pain (N=36; 56.3%), nausea and vomiting (N=30; 46.9%), diarrhea (n =24; 37.5%), dyspnea (n=24; 37.5%), hand and foot swelling (N=20; 31.3%), conjunctivitis (N=15; 23.4%), cough (N=12; 18.8%), and myalgia (N=12; 18.8%) (Table 1; Figure 2). The electrocardiogram (ECG) findings revealed severe tachycardia and significant ventricular dysfunction, which requires anticoagulation (Figure 2). One patient (n =1; 1.6%) was initially diagnosed with Kawasaki disease. A total of 16 (25.0%) children were admitted to the intensive care unit (ICU) support, among which, we identified 35 without any data (54.7%) (Table 1). Levels of C-reactive protein (75.0%), hemoglobin (51.6%), D-dimer (48.4%), lymphocytes (43.8%), LDH (45.3%), AST (42.2%), ALT (51.6%), and ferritin (48.4%) were above the reference values for a given age and gender (Table 2).

Data regarding the treatment were available for a total of 30 patients (46.9%). Among them, 22 (73.3%) received corticosteroids, of which metiprednilone (N=15; 68.2%) was the most common glucocorticoid prescribed. Another 23 (76.7%) patients received...
TABLE 1: Demographic, clinical and laboratory diagnosis features of 64 children and adolescents with MIS-C temporally associated with SARS-CoV-2 infection from Ceará, Brazil.

| Variable                                      | N = 64 |
|-----------------------------------------------|--------|
| Age, years, median (IQR)                      | 7(2.7-12.2) |
| Sex, female, n (%)                            | 33(51.6) |
| Pre-existing disease, n (%)                   | 5(7.8) |
| Cardiopathy                                   | 2(3.1) |
| Hematological disease                         | 1(1.6) |
| Neurological disease                          | 1(1.6) |
| Genetic disorders                              | 1(1.6) |
| Symptoms and signs, n (%)                     |        |
| Exanthema                                      | 39(60.9) |
| Abdominal Pain                                 | 36(56.3) |
| Nausea and vomits                             | 30(46.9) |
| Diarrhea                                       | 24(37.5) |
| Dyspnea                                        | 24(37.5) |
| Edema of the hands and feet                   | 20(31.3) |
| Conjunctivitis                                 | 15(23.4) |
| Cough                                         | 12(18.8) |
| Myalgia                                        | 12(18.8) |
| Irritability                                   | 9(14.1) |
| Skin color changes                            | 8(12.6) |
| Lethargy                                       | 5(7.8) |
| Oliguria                                       | 5(7.8) |
| Tachycardia                                    | 4(6.3) |
| Cervical edema                                 | 4(6.3) |
| Lymphadenopathy                                | 4(6.3) |
| Oxygen saturation less than 95%               | 4(6.3) |
| Odinophobia                                    | 3(4.7) |
| Dysphagia                                      | 2(3.1) |
| Precordial pain                                | 2(3.1) |
| Mental confusion                               | 1(1.6) |
| ICU admission, n (%)                           |        |
| Required                                       | 16 (25.0) |
| Not required                                   | 13(20.3) |
| Intensive Care Unit length of stay, days, median (IQR) | 6(3.8-9.3) |
| Laboratorial diagnosis, n (%)                  |        |
| RT-PCR                                         | 35 (54.7) |
| Antigen test                                   | 43(67.2) |
| Serology                                       | 11 (17.2) |
| Outcome variablesb                             |        |
| Discharge, n (%)                               | 58(90.6) |
| Fatal outcome, n (%)                           | 2(3.1) |
| Hospital length of stay, days, median (IQR)c   | 12(7-16) |

IQR, interquartile range; RT-PCR, real-time reverse transcription-polymerase chain reaction

aData missing for 35 patients.

bData missing for 4 patients.

cData missing for 6 patients.

intravenous immunoglobulin (2 g/kg), and 8 (26.7%) patients were anticoagulated with enoxaparin (Pre-term infants: 2 mg/kg/dose; Term to 2 months: 1.5 mg/kg/dose injected subcutaneously every 12 hours; Infants ≥ 2 months and children ≤18 years: 1 mg/kg/dose injected subcutaneously every 12 hours). Moreover, seven (23.4%) children needed antibiotic therapy due to a secondary infection with ceftriaxone.

The first reported case of death was a 15-year-old female without any pre-existing chronic conditions, who succumbed to death due to sepsis after 9 days of hospitalization. The second was a 13-year-old female patient with a history of acute myeloid leukemia, declared dead after 7 days of hospitalization, without any data regarding the cause of death. Both patients were confirmed for SARS-CoV-2 using RT-PCR.
TABLE 2: Laboratorial aspects of 64 children and adolescents with MIS-C temporally associated with SARS-CoV-2 infection from Ceará, Brazil.

| Laboratory            | +RV | -RV | N   | N/A |
|-----------------------|-----|-----|-----|-----|
| Hemoglobin            | 0   | 33  | 19  | 12  |
| White cell count      | 17  | 0   | 37  | 9   |
| Lymphocytes           | 0   | 28  | 25  | 11  |
| Platelets             | 23  | 0   | 31  | 10  |
| C-reactive protein    | 48  | 0   | 9   | 7   |
| D-dimer               | 31  | 0   | 17  | 15  |
| Creatinine            | 14  | 0   | 38  | 12  |
| Troponin              | 5   | 0   | 10  | 49  |
| LDH                   | 29  | 0   | 16  | 19  |
| AST                   | 27  | 0   | 28  | 9   |
| ALT                   | 33  | 0   | 21  | 10  |
| Ferritin              | 31  | 0   | 10  | 22  |

Legend: LDH: lactate dehydrogenase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; +RV: above reference values; -RV: below reference values; N: normal; N/A: not available.

These cases occur predominantly in the month of July, a month after the transmission of COVID-19 peaked. The average age of these children was 7 years (20 days-16 years). Ceará state was one of the first to confirm sustained transmission, as well as the first to show an escalation in the number of cases and deaths. However, the reported deaths due to COVID-19 was confirmed by a mobile death verification service that investigated the deaths which occurred at home.

MIS-C appears to be a clinical syndrome that shares aspects with other inflammatory conditions, wherein large amounts of cytokines cause the dysfunction of several organs and systems.
Our findings were similar to other studies that reported presence of indecisive comorbidities, different from adult patients; however, it may contribute to severity and mortality\textsuperscript{11}. This clinical picture represents a novel phenomenon that can affect previously asymptomatic children and young people with \textit{SARS-CoV-2} infection manifesting as a hyperinflammatory syndrome with multiorgan involvement. Clinical findings are very similar to those found in cases of Kawasaki disease, KD shock syndrome, MAS, and TSS, highlighting the need for proactive surveillance and creating awareness among health professionals regarding the symptoms and the importance of an early treatment. Some differences between MIS-C and KD may be noted, such as the predominance of gastrointestinal symptoms, left ventricular systolic dysfunction, shock, and markedly elevated inflammatory biomarkers. Our report described a high incidence of gastrointestinal symptoms (abdominal pain, nausea, vomiting, and diarrhea) and elevated inflammatory biomarkers, which are commonly present in most MIS-C series. Another essential difference between MIS-C and KD is the age of onset, with MIS-C being presented at an older age as compared to KD\textsuperscript{4,5}.

This study had several limitations. This retrospective study was conducted based on secondary data analysis. Although it represents one of the largest samples of MIS-C temporally associated with COVID-19 in the medical literature, it is still a small sample. Another major limitation is the absence of data regarding cardiac complications (myocarditis, pericarditis, and cardiac dysfunction), neurological, and renal involvement. Despite these limitations, this study provides relevant data on the pandemic settings. During the study period, there were no data regarding variant circulation such as P1 (from Manaus) and P2 (Rio de Janeiro), although genetic studies have shown that the variant N9 was born in August 2020.

All these cases occurred when interactive classes were suspended in schools, indicating that school was not the source of infection. As the reopening of schools is being planned, there has been an ongoing debate around the possibility of the infection manifesting as a hyperinflammatory syndrome in previously asymptomatic children and young people. This study provides relevant data on the pandemic settings. During the study period, there were no data regarding variant circulation such as P1 (from Manaus) and P2 (Rio de Janeiro), although genetic studies have shown that the variant N9 was born in August 2020.

ACKNOWLEDGMENTS

LPGC is recipient of the fellowship for research productivity granted by the Brazilian National Council for Scientific and Technological Development (CNPq/Brazil). EPISUS/MS team for field investigation.

FINANCIAL SUPPORT

This work was partially supported by the Network of Clinical and Applied Research into Covid-19 (REBRACOID) through funds from the Department of Science and Technology (DECIT), Brazilian Ministry of Health; by the National Council for Scientific and Technological Development; and by Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecnológico (FUNCAP).

AUTHORS’ CONTRIBUTION

I certify that all the authors have participated sufficiently in the conception and design of this work and the analysis of the data (where applicable and within each area of expertise), or the writing of the manuscript, and to take public responsibility for it. I warrant that this work is original and scientifically accurate, that it is not defamatory, does not invade any right of privacy, and does not infringe on any proprietary right or copyright. We believe the manuscript represents valid work. Description of each author’s role in the research process and in preparing the manuscript:

LABGF, PMCL, MAPS and LPGC responsible for drafting the proposal, review of literature and writing the article; LABGF, MMA, PMCL, BF, RJCDF, RDL, MAPS and LPGC drafting the paper or substantially revising it and was responsible for overall direction conception and design of the study.

CONFLICT OF INTEREST

MAPS received consultancy fees and research grants from Pfizer, Astra Zeneca and Janssen.

The other authors declare that there is no conflict of interest.

ORCID

Lucas Arthur Brasil Gadelha Farias: 0000-0002-8978-9903
Magda Moura de Almeida: 0000-0002-4806-2345
Pâmela Maria Costa Linhares: 0000-0002-5565-9393
Bruno Cavalcante Fales de Brito Alves: 0000-0002-7056-6726
Roberto Jorge Colares Duarte Filho: 0000-0003-2654-6637
Roberio Dias Leite: 0000-0003-4416-0543
Marco Aurelio Palazzi Safadi: 0000-0002-4401-9446
Luciano Pamplona de Góes Cavalcanti: 0000-0002-3440-1182

REFERENCES

1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3.
2. World Health Organization (WHO). Discurso de abertura do Diretor-Geral da OMS na conferência de imprensa sobre COVID-19, realizada em 11 de março de 2020 [Internet]. Genebra: WHO; 2020; Available at: https://www.who.int/es/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
3. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109:1088-95.
4. Radia T, Williams N, Agrawal P, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr Respir Rev. 2020;11:S1526-0542(20):30117-2.
5. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395:1607-8.
6. Ceara. Health's Secretary. Available at: https://indicadores.integratus.saude.ce.gov.br/indicadores/indicadores-coronavirus/coronavirus-ceara. Accessed on 02/10/2021.

7. World Health Organization. (2020). Global COVID-19 clinical platform: case record form for suspected cases of multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19, 01 June 2020. World Health Organization.

8. Lemos DRQ, D’Angelo SM, Farias LABG, Almeida MM, Gomes RG, Pinto GP et al. Health system collapse 45 days after the detection of COVID-19 in Ceará, northeast Brazil: a preliminary analysis. Rev Soc Bras Med Trop. 2020;53(e20200354).

9. Souza PMM, Gerson G, Dias JS, Melo DN, Souza SG, Ruiz ME, et al. Validation of verbal autopsy and nasopharyngeal swab collection for the investigation of deaths at home during the COVID-19 pandemics in Brazil. PLoS Negl Trop Dis. 2020;14:1-4.

10. Souza PMM, Gerson G, Dias JS, Melo DN, Tavora FRF, Soares CEL, et al. COVID-19 home deaths without medical assistance in Northeast of Brazil. Am J Trop Med Hyg. 2020;20:1-5.

11. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Filho MBF, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334–46.

12. Bittencourt MS, Bittencourt DP, Generoso G, Markus J, Moura C, Cossi J. Banco Interamericano de Desenvolvimento. COVID-19 e a reabertura das escolas: uma revisão sistemática dos riscos de saúde e uma análise dos custos educacionais e econômicos. 2021. Textos para debate nº IDB-DP-00842, p:55, 2021.